230 related articles for article (PubMed ID: 35355169)
41. Botulinum toxin A improves psychological distress in patients with hemifacial spasm.
Wang C; Zhu X; Xia L; Xie P; Tian X; Shang J; Han Q
Acta Neurol Belg; 2022 Feb; 122(1):43-49. PubMed ID: 33515182
[TBL] [Abstract][Full Text] [Related]
42. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
[TBL] [Abstract][Full Text] [Related]
43. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm.
Cakmur R; Ozturk V; Uzunel F; Donmez B; Idiman F
J Neurol; 2002 Jan; 249(1):64-8. PubMed ID: 11954870
[TBL] [Abstract][Full Text] [Related]
44. Hemifacial spasm non-motor and motor-related symptoms and their response to botulinum toxin therapy.
Rudzińska M; Wójcik M; Szczudlik A
J Neural Transm (Vienna); 2010 Jun; 117(6):765-72. PubMed ID: 20467763
[TBL] [Abstract][Full Text] [Related]
45. Ocular surface changes in primary open-angle glaucoma on anti-glaucoma medications versus treatment-naïve patients.
Srivastava K; Bhatnagar KR; Shakrawal J; Tandon M; Jaisingh K; Pandey L; Roy F
Indian J Ophthalmol; 2024 Mar; 72(3):374-380. PubMed ID: 38099355
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of Corneal Morphology in Patients With Hemifacial Spasm.
Ulusoy DM; Ulusoy EK; Duru Z; Çiçek A
Eye Contact Lens; 2019 Jul; 45(4):271-275. PubMed ID: 30946064
[TBL] [Abstract][Full Text] [Related]
47. The role of the injection botulinum toxin A in cases of blepharospasm syndrome, hemifacial spasm and Meige's syndrome.
Bastola P; Chaudhary M; Agrawal JP; Shah DN
Kathmandu Univ Med J (KUMJ); 2010; 8(31):305-10. PubMed ID: 22610735
[TBL] [Abstract][Full Text] [Related]
48. An investigation into the effects of ocular nebulization combined with meibomian gland massage on ocular surface status and corneal higher-order aberrations for the treatment of meibomian gland dysfunction.
Lin F; Mao X; Ma L; Liu H
Acta Ophthalmol; 2022 May; 100(3):e681-e693. PubMed ID: 34331838
[TBL] [Abstract][Full Text] [Related]
49. Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy.
Alexandru H; Muthuraman M; Chirumamilla VC; Koirala N; Paktas B; Deuschl G; Zeuner KE; Groppa S
PLoS One; 2016; 11(12):e0168652. PubMed ID: 27992533
[TBL] [Abstract][Full Text] [Related]
50. [Dry eye and qualitative tear alteration in essential blepharospasm].
Girard B; Begnaud S
J Fr Ophtalmol; 2022 Mar; 45(3):288-297. PubMed ID: 35148903
[TBL] [Abstract][Full Text] [Related]
51. Is optical coherence tomography an effective device for evaluation of tear film meniscus in patients with acne rosacea?
Eroglu FC; Karalezli A; Dursun R
Eye (Lond); 2016 Apr; 30(4):545-52. PubMed ID: 26768918
[TBL] [Abstract][Full Text] [Related]
52. Cataract Surgery Destabilises Temporary the Tear Film of the Ocular Surface.
Cung LX; Nga NTT; Nga DM; Hiep NX; Pham DT
Klin Monbl Augenheilkd; 2021 Mar; 238(3):282-287. PubMed ID: 32659842
[TBL] [Abstract][Full Text] [Related]
53. Frequency of Hemorrhagic Side Effects of Botulinum Neurotoxin Treatment in Patients with Blepharospasm and Hemifacial Spasm on Antithrombotic Medication.
Wenninger FC; Wabbels B
Toxins (Basel); 2022 Nov; 14(11):. PubMed ID: 36356019
[TBL] [Abstract][Full Text] [Related]
54. Paralysis of the orbicularis muscle of the eye using botulinum toxin type A in the treatment for dry eye.
Serna-Ojeda JC; Nava-Castaneda A
Acta Ophthalmol; 2017 Mar; 95(2):e132-e137. PubMed ID: 27350144
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of stigmatization in hemifacial spasm and quality of life before and after botulinum toxin treatment.
Yuksel B; Genc F; Yaman A; Goksu EO; Ak PD; Gomceli YB
Acta Neurol Belg; 2019 Mar; 119(1):55-60. PubMed ID: 30178181
[TBL] [Abstract][Full Text] [Related]
56. Pain relief in patients receiving periocular botulinum toxin A.
Harrison AR; Erickson JP; Anderson JS; Lee MS
Ophthalmic Plast Reconstr Surg; 2008; 24(2):113-6. PubMed ID: 18356715
[TBL] [Abstract][Full Text] [Related]
57. A Review of Tolerance and Safety Profiles of Long-Term Botulinum Neurotoxin Type A in Asian Patients with Hemifacial Spasm and Benign Essential Blepharospasm.
Lai KKH; Tsang A; Kuk AKT; Ko CKL; Chan E; Ko STC
Neuroophthalmology; 2021; 45(5):293-300. PubMed ID: 34566211
[TBL] [Abstract][Full Text] [Related]
58. Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma.
Agnifili L; Brescia L; Scatena B; Oddone F; Figus M; Perna F; Doronzo E; D'Ugo E; Mastropasqua L
J Glaucoma; 2020 May; 29(5):374-380. PubMed ID: 32079993
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm.
Li XH; Lin SC; Hu YF; Liu LY; Liu JB; Hong YC
Eye Sci; 2012 Dec; 27(4):178-81. PubMed ID: 23225838
[TBL] [Abstract][Full Text] [Related]
60. Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment.
Quagliato EM; Carelli EF; Viana MA
Clin Neuropharmacol; 2010; 33(1):27-31. PubMed ID: 20124784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
